Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

  • There is currently no data for NSCI

Sofant secures £2.3m funding led by EMV Capital

12 Aug 2020 12:28

RNS Number : 9471V
NetScientific PLC
12 August 2020
 

NetScientific plc

("NetScientific" or the "Company")

Sofant Technologies Ltd secures £2.3m in an oversubscribed funding round led by EMV Capital

NetScientific plc (AIM:NSCI), the transatlantic healthcare IP commercialisation group, announces that EMV Capital ("EMVC"), a proposed acquisition by NetScientific , reported today that it has led a £2.3m pre-series A syndicated round in Edinburgh-based 5G and Satcom antenna developer Sofant Technologies, with participation by Scottish Investment Bank , Old College Capital, Kelvin Capital Ltd and Wealth Club.

This transaction increases assets under advisory by EMV Capital in Sofant by a further £1.6m.

The proposal that NetScientific acquires 100% of EMVC undiluted share capital, is to be voted on at general meeting 24 August 2020, as outlined in the Shareholder Circular posted 6 August 2020.

The full details of the announcement are set out below.

# # #

Sofant Technologies Ltd secures £2.3m in an oversubscribed funding round to scale its 5G and Satcom antenna platform

Wednesday 12th August 2020

EMV Capital led a £2.3m pre-series A syndicated round in Edinburgh based 5G and Satcom antenna developer Sofant Technologies, with participation by Kelvin Capital Ltd, Old College Capital, Wealth Club and Scottish Investment Bank.

Sofant, a leader in radio frequency microelectromechanical systems (RF MEMS), is building a proprietary, highly efficient radio technology platform which addresses several challenges facing wireless communication systems. It is initially targeting applications in satellite communications and 5G where its technology reduces the power consumption of electronically scanned antenna arrays by more than 70%.

Sofant CEO David Wither said, "We are very pleased to have supportive investors who understand the value of semiconductor-based hardware. This funding will be used to complete the development of our core RF technology platform. It will also support our activities with an ecosystem of corporate partners who share Sofant's belief that RF MEMS will disrupt the market for high frequency SatCom and 5G antenna applications. It is a very exciting time for Sofant, and we look forward to working with our partners to change the way high frequency antenna systems are designed and built."

Dr. Ilian Iliev, Managing Director of EMV Capital commented, "We are delighted to continue supporting our portfolio company, Sofant, which has made great progress with their disruptive technology in an exciting market. Reliable and fast connectivity has never been more important for our society-which has only become clearer in response to the impact of Covid-19. Sofant are well positioned to build on their development and growth to provide a key enabling technology for this future."

Sofant Technologies plans to use this funding to integrate leading edge RF MEMS technology into a 1st-generation product, accelerate system integration with satellite network operators, and to capitalise on leading OEM collaboration interest.

Ends

 

About Sofant Technologies

www.sofant.com 

Sofant Technologies is a leading-edge radio technology company based in Edinburgh. The company is applying its proprietary RF MEMS technology to develop an extremely low power, low cost platform which solves power consumption and heat problems in 5G and satellite communications antenna systems. Sofant employs a fabless semiconductor business model which enables it to leverage long established high volume, low cost production methods. This positions Sofant to offer its customers game-changing performance with guaranteed scalability and low cost.

About EMV Capital

www.emvcapital.com 

EMV Capital Ltd (EMVC) is a London-based venture investor focused on B2B companies in industrial high-tech, energy, circular economy, smart cities, transportation, and healthcare. EMVC's investments in Europe, Israel and the US cover a range of technologies including robotics and AI, machine learning, materials science, IoT, advanced engineering, power electronics and medical devices. EMVC can help companies fast-track their investment readiness through its ecosystem of global corporations, advisors, and service providers.

EMVC's multidisciplinary team holds expertise in venture investment, corporate development, corporate finance and M&A. EMVC understands the importance and value of environmental sustainability and ethical investment principles, reflecting this within its investment thesis.

EMV Capital is an exclusive advisor to the EMVC Evergreen EIS Fund (http://emvcapital.com/eis_fund/).

EMV Capital Limited is an appointed representative of Sapphire Capital Limited, which is authorised and regulated by the Financial Conduct Authority.

 

About Kelvin Capital

www.kelvincapital.com

Kelvin Capital Ltd is a Scottish based, private investment fund, with over 220 angel investors and a diverse portfolio of 20 investee companies having made investments of over £30 million to date.

 

About Old College Capital

www.oldcollegecapital.co.uk 

Old College Capital (OCC) is the University of Edinburgh's in-house venture investment fund. It aims to support the University's research, staff and students by investing in high-growth, early stage businesses associated with the University.

# # #

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Following the publication of this announcement, this inside information is now considered to be in the public domain.

 

For more information, please contact:

NetScientific

Ilian Iliev, CEO Tel: +44 (0)20 3514 1800

 

WH Ireland (NOMAD, Financial Adviser and Broker)

Chris Fielding / Darshan Patel Tel: +44 (0)20 7220 1666

 

MO PR ADVISORY (Press Contact)

Mo Noonan Tel: +44 (0)78 7644 4977

 

About NetScientific

NetScientific PLC is a transatlantic healthcare IP commercialisation Group focused on technologies and companies that have the potential to treat chronic disease and significantly improve the health and well-being of people.

 

For more information, please visit the website at www.NetScientific.net

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCFLFFLTEIFLII
Date   Source Headline
16th Sep 20242:31 pmRNSPDS: Updated Results, VERSATILE-002 Phase 2 Trial
13th Aug 20243:57 pmRNSPDS Biotech: Business Update and Q2 2024 Results
2nd Aug 202412:21 pmRNSReplacement RNS: PDS Biotech Aligns with FDA
2nd Aug 20247:00 amRNSPDS Biotech Aligns with FDA on Phase 3 Trial
30th Jul 20247:00 amRNSQ-Bot Fundraising
10th Jul 202410:48 amRNSResult of AGM
18th Jun 20247:00 amRNSNotice of AGM
14th Jun 20242:10 pmRNSTR-1
14th Jun 20247:00 amRNSDirector/PDMR Shareholding
13th Jun 20247:00 amRNSPreliminary Results for the year ended 31 Dec 2023
31st May 20247:01 amRNSNotice of Results and Investor Presentation
31st May 20247:00 amRNSDeepTech Recycling: Fundraising, Business Update
28th May 20247:00 amRNSInvestment in Wanda, related party transactions
15th May 20242:32 pmRNSPDS Biotech: Business Update and Q1 2024 Results
13th May 20247:00 amRNSMartlet Capital: mandate and acquisition
10th May 20249:12 amRNSPDS Biotech: Clinical trial meets study endpoints
15th Apr 20247:00 amRNSProAxsis secures c.£1.8mn investment
27th Mar 20241:34 pmRNSPDS Strategy Update and 2023 Financial Results
13th Mar 20247:00 amRNSBusiness Update
5th Feb 20247:00 amRNSExercise of Options and Issue of Shares
23rd Jan 20247:00 amRNSGlycotest secures $1 million investment
1st Dec 20237:00 amRNSDeepTech Recycling secures £1 million investment
14th Nov 20234:39 pmRNSPDS BioTechnology: Third Quarter Results
13th Nov 20237:00 amRNSDirector/PDMR Shareholding
9th Nov 20235:28 pmRNSPDS Biotech Announces Updated Survival Data
6th Nov 20237:00 amRNSVentive secures c.£900,000 investment
2nd Nov 20237:00 amRNSChange of Adviser
23rd Oct 20236:22 pmRNSPDS Preliminary Biomarker Study Results
13th Oct 20237:00 amRNSExercise of Options
3rd Oct 20234:12 pmRNSDirector/PDMR Shareholding
3rd Oct 20233:21 pmRNSPDS: Interim 24-month survival rate of 74% update
3rd Oct 20237:00 amRNSPDS Biotech: new data on PDS0101
28th Sep 20237:00 amRNSInterim Results
13th Sep 20237:00 amRNSQ-Bot: £3.5 million investment to drive expansion
14th Aug 20235:55 pmRNSPDS Biotech: 2nd Quarter Results, Business Update
14th Aug 20235:51 pmRNSPDS Biotech: Submission of Phase 3 Protocol to FDA
3rd Jul 20237:00 amRNSGrant of Options, Issue of Shares, Director/PDMR
30th Jun 20237:00 amRNSDName-iT Holdings Limited Fundraising
29th Jun 202311:04 amRNSResult of AGM & Board Changes
22nd Jun 20237:00 amRNSVortex Fundraising
14th Jun 20233:31 pmRNSPDS Announces Achievement of Efficacy Threshold
7th Jun 20237:00 amRNSDirector/PDMR Shareholding
6th Jun 20237:00 amRNSNotice of AGM
31st May 20237:01 amRNSPreliminary Results for the year ended 31 Dec 2022
31st May 20237:00 amRNSBoard Changes
26th May 20239:39 amRNSPDS Biotech Announces Interim Data
24th May 20237:00 amRNSSofant and Inmarsat announce joint development
15th May 20233:16 pmRNSPDS Business Update and First Quarter Results
2nd May 20237:00 amRNSGlycotest, Inc. Fundraising
3rd Apr 20237:00 amRNSBusiness Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.